Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15,857 Mln
Revenue (TTM)
$14,322 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
16.8
P/B Ratio
2.7
Industry P/E
--
EV/EBITDA
14.7
Div. Yield
0 %
Debt to Equity
1
Book Value
$59.3
EPS
$9.8
Face value
--
Shares outstanding
613,910,580
CFO
$24,654.60 Mln
EBITDA
$30,917.84 Mln
Net Profit
$24,512.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
| -10.7 | -6.6 | -10.7 | 47.4 | -10.0 | -3.5 | 6.9 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Midcap 400
| 1.8 | -4.7 | 3.1 | 16.1 | 10.7 | 5.2 | 8.9 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
| 47.6 | -34.2 | -24.9 | 7.1 | -2.7 | 82.1 | 36.5 |
|
S&P Midcap 400
| 5.9 | 12.1 | 14.4 | -14.5 | 23.2 | 11.8 | 24.1 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Genmab A/S ADS - ADR
|
27.5 | 15,857.3 | 23,728.1 | 6,142.5 | 24.2 | 16.6 | 16.8 | 2.7 |
| 746.4 | 43,711.5 | 4,164.2 | 1,296.0 | 9.5 | 20.2 | 36 | 5.6 | |
| 3.4 | 311.8 | 73.2 | -67.8 | -55.3 | -65.5 | -- | 4.1 | |
| 21.1 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.4 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.4 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 16.6 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.3 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 6.1 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 | |
| 20.4 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R)... diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark. Address: Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500 Read more
Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
Co-Founder, President & CEO
Dr. Jan G.J. van de Winkel Ph.D.
Headquarters
Copenhagen
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Genmab A/S ADS - ADR is $27.50 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Genmab A/S ADS - ADR has given a return of -10.03% in the last 3 years.
The P/E ratio of Genmab A/S ADS - ADR is 16.77 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
3.14
|
0.52
|
|
2024
|
1.72
|
0.37
|
|
2023
|
4.82
|
0.66
|
|
2022
|
5.13
|
1.03
|
|
2021
|
8.83
|
1.18
|
The 52-week high and low of Genmab A/S ADS - ADR are Rs 34.68 and Rs 17.24 as of 04-Apr-2026.
Genmab A/S ADS - ADR has a market capitalisation of $ 15,857 Mln as on 31-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Genmab A/S ADS - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.28
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.